Commercialization Reports. Without limiting Section 5.4, within [***] days following the end of each [***], during the Royalty Term, Mereo shall provide to AstraZeneca a written summary of the Commercialization activities it has performed, or caused to be performed, including a summary of all relevant financial data relating to such activities since the preceding report.
Appears in 5 contracts
Sources: Amendment and Restatement Agreement (Mereo BioPharma Group PLC), Exclusive License and Option Agreement, Exclusive License and Option Agreement (Mereo Biopharma Group PLC)